Delucchi A, et al. - Since renal transplantation (RTx) is an effective therapy to improve clinical outcomes in paediatric patients with terminal chronic kidney disease, however, chronic immunosuppression with glucocorticoids (GC) reduces bone growth and mineral density, researchers tested the assumption that GC impairs bone growth by increasing fibroblast growth factor 23 (FGF23) expression, which has direct effects on bone growth plate. According to findings, GC treatment partially decreases longitudinal bone growth by upregulation of FGF23 and FGFR3 expression, indicating that the FGF23/Klotho/FGFR3 axis at the growth plate could be a potential therapeutic target for the management of GC-induced growth impairment in children.